• Contact Us

• Press Releases
• Press Release Archives
• Events

Press Releases

• 09/28/13
  Jennerex Announces Expansion of Intellectual Property Portfolio
• 09/03/13
  Jennerex announces preliminary results from TRAVERSE, a Phase 2 study in second-line advanced liver cancer
• 05/23/13
  Jennerex Completes $21.6 Million Private Placement
• 05/21/13
  Jennerex Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
• 05/15/13
  Jennerex Presents Pexa-Vec Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting
• 05/15/13
  Jennerex Announces Science Translational Medicine Publication Highlighting Pexa-Vec's Ability to Induce Functional Anti-cancer Immunity in Patients with Diverse Tumor Types
• 05/08/13
  Jennerex Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
• 04/09/13
  Jennerex Announces Presentation of Data Demonstrating Pexa-Vec's Vascular Targeting Mechanism
• 02/25/13
  Jennerex and Lee's Pharmaceutical Announce Expansion of Partnership for Additional Pexa-Vec Indications in China
• 02/11/13
  Jennerex Announces Cancer Research Publication Demonstrating Vascular Targeting Mechanism of Action of Lead Product Candidate, Pexa-Vec (JX-594)
• 02/10/13
  Jennerex Announces Nature Medicine Publication Highlighting Randomized Overall Survival Benefit of Lead Product Candidate, Pexa-Vec (JX-594) in Patients with Advanced Hepatocellular Carcinoma (HCC)
• 11/27/12
  Jennerex’s Drug Candidate, JX-929, Named as One of the Top 10 Oncology Projects to Watch
• 11/08/12
  Jennerex to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
• 09/17/12
  Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX594 in Sorafenib-Refractory Liver Cancer Patients
• 07/25/12
  Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
• 06/28/12
  Jennerex Appoints Dr. Laurent Fischer as President and
  Chief Executive Officer
• 06/04/12
  Jennerex Presents JX-594 Clinical Data at 2012 American Society of Clinical Oncology Annual Meeting
• 05/16/12
  Jennerex Announces Data Presentations Relating to Oncolytic Virus JX-594 at American Society of Clinical Oncology Annual Meeting
• 04/17/12
  Jennerex Elects Dr. Mitchell H. Gold to Board of Directors
• 03/20/12
  Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
• 02/08/12
  Jennerex, Inc. to Present at the 14th Annual BIO CEO & Investor Conference
• 02/07/12
  Jennerex Publishes Data on JX-594 Cancer Targeting Mechanisms
• 12/21/11
  Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
• 11/05/11
  Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer
• 11/04/11
  Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
• 11/02/11
  Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
• 09/06/11
  Jennerex Presents Interim Clinical Data of JX-594 Followed by Sorafenib Demonstrating Tumor Responses in Liver Cancer
• 08/31/11
  Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX 594 to Tumors
• 08/11/11
  Jennerex Completes Successful Private Placement for Gross Proceeds of $8.6 Million
• 08/01/11
  Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
• 05/19/11
  Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
• 05/12/11
  Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
• 04/20/11
  Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination with Sorafenib in Advanced Liver Cancer
• 04/05/11
  Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
• 04/04/11
  Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients with Liver Tumors
• 02/22/11
  Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
• 01/19/11
  Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs